Tarveda Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins^®) for the treatment of patients with a wide range of solid tumors, today announced that Drew Fromkin, President and Chief Executive Officer, will present at Cowen’s 39^th Annual Health Care Conference, occurring March 11-13, 2019 in Boston, MA. Tarveda presentation details:

Date: Monday, March 11, 2019
Time: 4:30pm Eastern Time
Location: Boston Marriott Copley Place, Boston, MA

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. is discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins^®) for the treatment of patients with a wide range of solid tumors. Tarveda’s first drug candidate, PEN-221, is a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors. PEN-221 comprises a peptide that is highly selective for SSTR2 conjugated to the potent cytotoxic payload, DM1, through a tuned cleavable linker. Tarveda is also advancing its HSP90 binding drug conjugate platform with lead drug candidate PEN-866, which selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its SN-38 payload, a potent topoisomerase 1 inhibitor. Tarveda’s strategy includes developing its own proprietary miniature drug conjugates as well as applying its miniature drug conjugate platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. www.tarvedatx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005411/en/